CD274 and gastric cancer: The subsequent phase III KEYNOTE-61 trial found that pembrolizumab did not significantly improve the median overall survival (OS) compared to paclitaxel (9.1 vs. 8.3 months, hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.66–1.03; one-sided p = 0.0421) for advanced GC with a PD-L1 CPS ≥ 1 [13].